Experimental KRAS blocker tested in advanced cancers – trial halted early
NCT ID NCT06599502
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new oral drug, AZD0022, designed to block the KRASG12D mutation found in some advanced cancers like lung, pancreatic, and colorectal cancer. The study aimed to see if the drug was safe and tolerable when given alone or with another cancer drug (cetuximab). Only 17 people took part before the trial was stopped early, so we have limited information on how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD0022 (a drug that blocks the KRASG12D mutation) and cetuximab (a targeted antibody)
What this could lead to
If successful, this could point toward a new treatment option for cancers with the KRASG12D mutation, like some lung, pancreatic, and colorectal cancers.
What could go wrong
This was a very early (phase I/IIa) trial that was terminated early with only 17 participants, so results are limited. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
New York, New York, 10016, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Melbourne, 3000, Australia
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Seoul, 03080, South Korea